The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Amanda Holden puts on a VERY leggy display in a grey mini
Displaced Lebanese long for home as Hezbollah
Commanders hire Dave Gardi as senior VP of football initiatives
Kevin Pillar gets 1,000th career hit in Angels' win at Texas
Audit report finds German green transition lags behind targets
Thailand to waive visa requirements for Chinese nationals
Reggie Yates' fans send heartfelt congratulations after he delightedly shares baby news
Rangers are undefeated at .500 to keep World Series champs from a losing record with Bochy
Rihanna showcases her impeccable style in a quirky fur coat as she secures front
Georgia Republicans choose Amy Kremer, organizer of pro
China's national political advisory body holds leadership meeting